CytoTools AG - Product Pipeline Review - 2015

Date: August 26, 2015
Pages: 29
Price:
US$ 1,500.00 US$ 1,200.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C287C9C38B9EN
Leaflet:

Download PDF Leaflet

CytoTools AG - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘CytoTools AG - Product Pipeline Review - 2015’, provides an overview of the CytoTools AG’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CytoTools AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of CytoTools AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of CytoTools AG’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the CytoTools AG’s pipeline products
Reasons to buy
  • Evaluate CytoTools AG’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of CytoTools AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the CytoTools AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of CytoTools AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of CytoTools AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of CytoTools AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
CytoTools AG Snapshot
CytoTools AG Overview
Key Information
Key Facts
CytoTools AG - Research and Development Overview
Key Therapeutic Areas
CytoTools AG - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
CytoTools AG - Pipeline Products Glance
CytoTools AG - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
CytoTools AG - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
CytoTools AG - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
CytoTools AG - Drug Profiles
CL-05
Product Description
Mechanism of Action
R&D Progress
PEP-04
Product Description
Mechanism of Action
R&D Progress
HMW-02Ak
Product Description
Mechanism of Action
R&D Progress
HMW-02Ap
Product Description
Mechanism of Action
R&D Progress
LMW-0X
Product Description
Mechanism of Action
R&D Progress
CytoTools AG - Pipeline Analysis
CytoTools AG - Pipeline Products by Route of Administration
CytoTools AG - Pipeline Products by Molecule Type
CytoTools AG - Recent Pipeline Updates
CytoTools AG - Dormant Projects
CytoTools AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

CytoTools AG, Key Information
CytoTools AG, Key Facts
CytoTools AG - Pipeline by Indication, 2015
CytoTools AG - Pipeline by Stage of Development, 2015
CytoTools AG - Monotherapy Products in Pipeline, 2015
CytoTools AG - Pre-Registration, 2015
CytoTools AG - Phase III, 2015
CytoTools AG - Phase II, 2015
CytoTools AG - Phase I, 2015
CytoTools AG - Preclinical, 2015
CytoTools AG - Discovery, 2015
CytoTools AG - Pipeline by Route of Administration, 2015
CytoTools AG - Pipeline by Molecule Type, 2015
CytoTools AG - Recent Pipeline Updates, 2015
CytoTools AG - Dormant Developmental Projects,2015
CytoTools AG, Subsidiaries

LIST OF FIGURES

CytoTools AG - Pipeline by Top 10 Indication, 2015
CytoTools AG - Pipeline by Stage of Development, 2015
CytoTools AG - Monotherapy Products in Pipeline, 2015
CytoTools AG - Pipeline by Top 10 Route of Administration, 2015
CytoTools AG - Pipeline by Top 10 Molecule Type, 2015
Skip to top


EpiVax, Inc. - Product Pipeline Review - 2016 US$ 1,500.00 Jun, 2016 · 36 pages

Ask Your Question

CytoTools AG - Product Pipeline Review - 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: